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Gender Differences in ADHD Adults During Clinical Trials with Atomoxetine
Past research shows that ADHD is much more common in males particularly in
pediatric samples. Children exhibit few gender differences on a consistent basis
except in the area of associated symptoms. The present study addresses
whether ADHD adults displayed gender differences at screening or in treatment
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The data were taken from two identical placebo-controlled studies of
atomoxetine in adult ADHD1. Patients with depression, anxiety, or other
psychiatric diagnoses were excluded from the study. After a placebo washout,
535 subjects at 31 sites completed the 8-week double-blind period. The studies
showed positive medication-placebo differences and were the pivotal studies
leading the FDA to approve atomoxetine as the first non-stimulant medication for
the treatment of ADHD in adults.
The primary analysis of baseline measures was a comparison of gender-defined
groups. The student T-test was used for continuous variables, the Mann-
Whitney was used for ordinal data, and the Chi Square was used for nominal
data.
Improvement on all measures (except the CGI-S) was examined using
ANCOVA, controlling for baseline measures and looking for a gender by
treatment effect. Improvement on the CGI-S was evaluated using ANOVA.
ABSTRACT
Introduction: Patients with ADHD exhibit several consistent gender
differences, a male preponderance and more males with externalizing disorders
(conduct and oppositional defiant disorder).
Objective: To examine gender differences in a very large clinical trial of adults
with ADHD.
Methods: Data from two identical placebo-controlled studies of atomoxetine in
adult ADHD using 535 subjects at 31 sites were combined1. The studies lasted
8 weeks and both showed positive medication-placebo differences. Most
current Axis-I diagnoses were exclusionary criteria.
Results: The male/female ratio of this self-referred population was 2.4:1, lower
than in child studies2. In contrast to a predominance of an inattentive ADHD
diagnosis subtype in female children, these adult females were more frequently
combined type versus the males. Females were rated as more impaired on
every measure of ADHD symptoms including total CAARS-INV, total
WRAADDS3, and subscales of both measures. Females were rated as having
more emotional symptoms on the WRAADDS emotional dimension, lifetime
SCID-P psychiatric diagnoses, HAM-A, and HAM-D. Females exhibited
significantly greater improvement on the WRAADDS emotional dimension but
not on similar items in the Psychological Well-Being Scale. There were no
significant gender by treatment effects in the CAARS-INV or CGI-S scores.
Conclusion: These females with ADHD displayed significantly greater ADHD
symptoms and emotional impairment on multiple measures. On the WRAADDS
emotional dimension they responded better to treatment, than their male
counterparts.
There were relatively more women than in studies of ADHD in children. In contrast to
a childhood ratio of 3.4:1 in epidemiological studies2 and 6:1 in clinic-referred
populations, the male/female ratio was 2.4:1.
Seventy-five percent of females were as having diagnosed combined type ADHD, a
significantly higher rate than the males.
FIGURE 1: PERCENT IMPROVEMENT IN WRAADDS AFTER TX
TABLE 6: IMPROVEMENT OF WRAADDS, CAARS-INV & CGI
Female Male Tx by 
Gender
Atomoxetine Placebo Atomoxetine Placebo p Value
WRAADDS Total 5.6 (30%) 2.8 (16%) 4.8 (28%) 3.1 (19%) .269
Attention/Disorganization 1.8 (38%) 1.3 (19%) 1.8 (27%) 1.0 (16%) .548
Hyperactivity/Impulsivity 1.7 (30%) 1.1 (19%) 1.5 (28%) 0.9 (18%) .896
Emotional Dysregulation 2.1 (34%) 0.4 (7%) 1.5 (28%) 0.7 (14%) .011
CAARS-INV Total 14.1 (36%) 9.7 (25%) 12.8 (35%) 9.4 (26%) .433
Inattentiveness 7.2 (34%) 4.6 (22%) 6.8 (33%) 5.1 (25%) .289
Hyperactivity 6.9 (39%) 5.0 (29%) 6.0 (37%) 4.3 (27%) .789
CGI-S 3.8±1.2 4.4±1.2 3.9±1.1 4.1±1.0 .134
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Attention/Disorganization Hyperactivity/Impulsivity Emotional Dysregulation
On the Psychological General Well-Being Questionnaire, both males and females
showed the highest symptom levels on tension-anxiety and energy-drive, with lesser
elevations on mood. The lowest symptom levels were on psychological control,
mood, and somatic symptoms.
Females showed more impairment than males in total CAARS-INV and in total
WRAADDS, and females showed more symptoms of emotional dysregulation as well
as the other sub-scales of these two measures.
Females were more likely than males to have siblings and children with ADHD.
Both genders demonstrated significant atomoxetine/placebo treatment effects.
However, on the WRAADDS, emotional dysregulation improved more in females
after receiving atomoxetine than in males. In contrast, both genders experienced
treatment effects in two Psychological Well-Being Scales - Mood and Anxiety.
These adults with ADHD displayed multiple significant gender differences. Women
usually displayed more impairment than men, especially in symptoms of emotional
dysregulation. This discrepancy with many childhood findings may be due to
dissimilar referral biases. While children are referred by parents and teachers, often
because of conflicts with others, these patients are self-referred. Women with ADHD
were also more likely to have a family history of ADHD. These data suggest that
women, although often undertreated and underdiagnosed, represent a significant
subset of ADHD patients and that adult females with ADHD may benefit substantially
from treatment.
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TABLE 2: MEASURES OF ADHD AT BASELINE
Female Male p Value1
Total WRAADDS 18.2±4.4 16.7±5.2 .001
Attention/Disorganization 6.9±1.2 6.5±1.4 .007
Hyperactivity/Impulsivity 5.5±1.6 5.1±1.9 .010
Emotional Dysregulation 5.8±2.8 5.0±2.9 .002
Total CAARS-INV 38.9±6.4 36.3±7.5 .000
Inattention 21.3±3.4 20.4±3.9 .004
Hyperactivity 17.6±4.8 15.9±5.4 .000
TABLE 1: ADHD DIAGNOSIS CATEGORY
Female Male
Hyperactive/Impulsive 1 (1%) 12 (3%)
Inattentive 46 (24%) 121 (35%)
Combined 141 (75%) 213 (62%)
1) ADHD Diagnosis Category : X2=11.79, df=2, p=.005
TABLE 3: FAMILY HISTORY OF ADHD
Female Male p Value
Father 14% 14% ns
Mother 13% 12% ns
Grandparents 3% 3% ns
Siblings 31% 22% .03
Children 61% 46% .01
Any 66% 52% .05
TABLE 4: LIFETIME SCID-P DIAGNOSIS, HAM-A AND HAMD-17
Female Male p Value 
N 188 346
Depression 33 (18%) 34 (10%) .05
Anxiety 10 (5%) 7 (2%) ns 
Substance Abuse 13 (7%) 23 (7%) ns 
Any Diagnosis 44 (23%) 52 (15%) .02
Total HAM-A 7.9±5.4 6.6±4.7 .003
Total HAMD-17 5.7±4.1 4.9±3.6 .020
TABLE 5: PSYCHOLOGICAL WELL-BEING AT BASELINE*
Female Male p Value
N 136 251
Mood 21 (15%) 46 (18%) ns
Life Satisfaction 68 (50%) 130 (52%) ns
Anxiety 65 (48%) 112 (45%) ns
Control 37 (27%) 61 (24%) ns
Energy 70 (51%) 111 (44%) ns
Somatic 21 (15%) 30 (12%) ns
*Number of patients who had an average score of greater than 3 in each category on 
the General Psychological Well-Being Questionnaire.  Questions are scored on a 
scale of 1-6, with 6 being most impaired.
